Altimmune, Inc. (ALT) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-05-01

Key Insights

Director Teri L Lawver received a grant of 48,800 stock options with a $2.82 exercise price, vesting over 12 months starting May 1, 2026, indicating the company is using equity compensation for board retention.
The option grant to a non-employee director under the company's compensation policy reflects standard governance practices for maintaining board continuity and aligning director interests with shareholders.
No direct insider buying or selling activity was reported in this transaction—this is purely a non-employee director compensation grant with no immediate cash outlay or market signal about management's view of company valuation.

Want the newest filings?

This analysis covers the filing from 2026-05-01. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-05-01

Director Catherine A. Sohn received a grant of 48,800 stock options with an exercise price of $2.82, vesting monthly over 12 months from May 1, 2026, representing standard non-employee director compensation.
The option grant size of 48,800 shares is relatively modest and typical for director-level equity compensation, suggesting routine governance practices without unusual wealth concentration.
Zero shares are currently beneficially owned following this transaction, indicating this is a new option grant to the director rather than evidence of significant insider confidence through direct stock purchases.

Filed: 2026-05-01

Director Diane Jorkasky received a grant of 48,800 stock options with an exercise price of $2.82, vesting monthly over 12 months from May 1, 2026, indicating standard non-employee director compensation.
The option exercise price of $2.82 may reflect the company's stock trading level on the grant date; this provides context for evaluating the director's compensation value relative to current market conditions.
As a director (not an officer), this transaction represents routine equity compensation rather than discretionary insider buying, suggesting no signal about management's confidence in near-term stock performance.

Filed: 2026-05-01

Director Klaus Schafer received a grant of 48,800 stock options with an exercise price of $2.82, vesting monthly over 12 months from May 1, 2026, representing a routine non-employee director compensation action rather than a significant insider transaction.
The option grant shows the company's stock price was at or near $2.82 on the grant date, providing a reference point for current valuation levels that investors can use for context.
No actual shares were acquired or disposed of in this filing—only options were granted—indicating this is a non-material compensation event with no immediate change to insider share ownership or voting power.

Filed: 2026-05-01

Director Wayne Pisano received a grant of 48,800 stock options with an exercise price of $2.82, vesting monthly over 12 months from May 1, 2026, representing standard non-employee director compensation rather than discretionary insider buying.
The relatively modest option grant size and vesting schedule suggest routine director compensation practices, with no indication of significant insider confidence or concern about the company's near-term prospects.
This is a standard equity grant to a board member with no material trading activity, derivative positions, or changes in beneficial ownership that would signal meaningful insider sentiment about Altimmune's valuation or strategic direction.

Filed: 2026-05-01

Director Philip Hodges received a grant of 48,800 stock options at an exercise price of $2.82, vesting monthly over 12 months, representing routine non-employee director compensation rather than a significant insider transaction.
The option grant demonstrates continued board engagement and retention efforts, with vesting conditions tied to ongoing service through the applicable vesting dates.
This is a standard equity compensation grant rather than open-market buying or selling activity, indicating no material change in insider confidence regarding the stock's near-term direction.

Filed: 2026-05-01

Director John Gill received a grant of 48,800 stock options with an exercise price of $2.82, vesting over 12 months starting May 1, 2026, representing standard non-employee director compensation rather than a discretionary insider purchase.
The option exercise price of $2.82 suggests the stock was trading near this level on the grant date, providing a baseline for assessing future stock performance and insider confidence in company valuation.
This is a routine equity grant to a board member under the company's non-employee director compensation policy, with no indication of material insider selling or significant changes in board-level conviction about the company's prospects.

Filed: 2026-05-01

Non-employee director Sayare Mitchel received a grant of 48,800 stock options with a strike price of $2.82 on May 1, 2026, vesting monthly over 12 months, indicating standard director compensation rather than unusual insider activity.
The option grant is relatively modest in size and structured as routine director compensation under the company's non-employee director compensation policy, suggesting no material concerns about insider confidence or significant changes in company direction.
No sale or disposition of existing shares is reported, only the grant of new equity compensation, which is typical for board members and does not indicate meaningful insider selling pressure or loss of confidence in the stock.

Filed: 2026-04-06

Insider John Gill has purchased 9,200 shares of Altimmune, Inc. (ALT) at a weighted average price of $3.4076 per share, increasing his direct ownership to 21,700 shares.
The insider purchase represents a vote of confidence in the company by a director, which could be viewed positively by investors.
The timing of the purchase, shortly after the start of the year, suggests the director may have a positive outlook on the company's near-term prospects.

Filed: 2026-04-01

Insider Jerome Benedict Durso, President and CEO of Altimmune, Inc., acquired 15,000 shares of common stock at $3.14 per share, increasing his direct ownership to 47,500 shares.
The insider purchase suggests Durso's confidence in Altimmune's prospects and aligns his interests with those of other shareholders.
The transaction date of April 1, 2026 may indicate Durso's belief in the company's near-term growth potential.

Filed: 2026-04-01

Insider Gregory Weaver, the Chief Financial Officer of Altimmune, Inc. (ALT), purchased 10,000 shares of the company's common stock at a weighted average price of $3.1499 per share.
This insider purchase represents a direct increase in Weaver's beneficial ownership of Altimmune stock, which now stands at 38,078 shares.
Insider buying can be a positive signal to investors, as it suggests the executive has confidence in the company's future prospects.

Filed: 2026-03-09

The CEO of Altimmune, Inc. (ALT) Jerome Benedict Durso has purchased 20,000 shares of the company's common stock at a weighted average price of $3.5395 per share, increasing his direct ownership to 32,500 shares.
This insider buying activity suggests that the CEO is confident in the company's prospects and believes the current stock price represents an attractive investment opportunity.
Investors should monitor any further insider buying or selling patterns, as they can provide insights into management's views on the company's future performance.

Filed: 2026-03-09

Gregory L. Weaver, the Chief Financial Officer of Altimmune, Inc., has purchased 5,000 shares of the company's common stock at $3.54 per share, indicating his confidence in the company's future prospects.
This transaction increases Weaver's beneficial ownership in Altimmune to 28,078 shares, demonstrating his alignment with the interests of the company and its shareholders.
Insider purchases, especially by C-suite executives, can be viewed as a positive signal by investors, as it suggests management's belief in the company's growth potential.

Filed: 2026-01-29

The reporting person, Raymond M. Jordt, who serves as the Chief Business Officer, exercised 15,850 restricted stock units (RSUs) and sold 4,229 shares to cover taxes, indicating ongoing equity holdings and commitment to the company.
The vesting schedule for the remaining 47,550 RSUs is structured over the next 4 years, suggesting a long-term incentive alignment between the executive and Altimmune's performance.
The transaction price of $6.18 per share for the shares sold to cover taxes is in line with Altimmune's recent trading range, reflecting typical equity compensation practices.

Filed: 2026-01-29

The reporting person, Vipin K. Garg, is a director at Altimmune, Inc. and has exercised 41,200 restricted stock units (RSUs), indicating their continued commitment to the company.
Garg has also disposed of 17,898 shares to cover taxes associated with the RSU vesting, suggesting prudent financial planning.
The total number of shares beneficially owned by Garg following the reported transactions is 402,450, representing a significant ownership stake in the company.

Filed: 2026-01-29

The reporting person, M Scot Roberts, exercised 15,850 restricted stock units (RSUs) of Altimmune, Inc. (ALT) on January 27, 2026, indicating continued confidence in the company's long-term prospects.
Roberts surrendered 4,748 shares to cover taxes associated with the RSU vesting, suggesting he is maintaining a significant equity stake in the company.
The RSUs vest over 4 years, aligning Roberts' incentives with long-term shareholder value creation.

Other reports for Altimmune, Inc.

Current Report Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.